2025 Annual Meeting | Industry Theraepeutic Update from Novartis Pharmaceuticals: From data to experience: Early considerations for an established B-cell therapy for RMS with long-term patient results

��ɫ��

2025 Annual Meeting | Industry Theraepeutic Update from Novartis Pharmaceuticals: From data to experience: Early considerations for an established B-cell therapy for RMS with long-term patient results

Date Monday 04/07/25

Time 11:45 AM - 12:45 PM PDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Stephen W. Yeung, DO, Christine Racchini, PharmD

Topic(s) General Neurology, Multiple Sclerosis

Learning Objectives Bridging data and patient experience to deliver practical insights for the early use of an established B-cell therapy in patients with RMS.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM PDT	Speaker	Industry Theraepeutic Update from Novartis Pharmaceuticals: From data to experience: Early considerations for an established B-cell therapy for RMS with long-term patient results

Faculty Disclosures
Stephen W. Yeung, DO	Dr. Yeung has received personal compensation for serving as an employee of Novartis.
Christine Racchini, PharmD	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��